Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data
Veraxa Biotech’s split-component antibody-drug conjugate platform could reduce off-tumour toxicity, but investors received laboratory evidence rather than the clinical roadmap needed to support its newly public valuation.